Based on the forecasted data:
- 2024: €976.5M
- 2025: €991.3M
- 2026: €1000.0M
- 2027: €1010.0M
- 2028: €1020.0M
The year-on-year variations are as follows:
- 2025 vs 2024: 1.52%
- 2026 vs 2025: 0.88%
- 2027 vs 2026: 1.00%
- 2028 vs 2027: 0.99%
CAGR (2024-2028): 1.09%
The forecasted data shows a steady, albeit modest, growth in Renin-Angiotensin System medicine sales in Spain. Future trends to watch include advancements in related pharmaceutical technologies, evolving regulatory landscapes, and demographic changes impacting the prevalence of related conditions.
